Scalper1 News
Big pharma Merck (MRK) missed sales estimates in its Q4 results and 2014 guidance Wednesday, but the stock hit a six-year high anyway after it announced a new set of deals in its cancer program. Merck said profit in the most recent quarter totaled 88 cents a share, up 6% from the year-earlier quarter and in line with analysts’ consensus. Sales shrank 4% to $11.32 billion, a bit below consensus of $11.36 billion. The 2014 guidance followed a Scalper1 News
Scalper1 News